GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 472
- Registration Number
- NCT05412030
- Locations
- πΊπΈ
GSK Investigational Site, South Jordan, Utah, United States
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma
- Conditions
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT05398198
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT05393076
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- πΏπ¦
GSK Investigational Site, Cape Town, South Africa
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3038
- Registration Number
- NCT05371080
- Locations
- π¬π§
GSK Investigational Site, Liverpool, United Kingdom
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT05340257
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT05334368
- Locations
- π¬π§
GSK Investigational Site, Leicester, United Kingdom
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 132
- Registration Number
- NCT05330455
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 217
- Registration Number
- NCT05305651
- Locations
- π¬π§
GSK Investigational Site, Plymouth, United Kingdom
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05304130